In vivo and in vitro antiarrhythmic effects of SSR149744C in animal models of atrial fibrillation and ventricular arrhythmias

Journal of Cardiovascular Pharmacology

Volumn 45, Issue 2, 2005, Pages 125-135

  Gautier, Patrick ^a   Serre, Martine ^a   Cosnier Pucheu, Sylvie ^a   Djandjighian, Laurent ^a   Roccon, Alain ^a   Herbert, Jean Marc ^a   Nisato, Dino ^a  

^a SANOFI   (France)

Author keywords

Amiodarone; Animal model; Antiarrhythmic; SSR149744C

Indexed keywords

2 BUTYL 3 [4 [3 (DIBUTYLAMINO)PROPYL]BENZOYL] 1 BENZOFURAN 5 CARBOXYLATE ISOPROPYL FUMARATE; AMIODARONE; BENZOFURAN DERIVATIVE; DRONEDARONE; SSR 149744C; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DOG; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ELECTROPHYSIOLOGY; GUINEA PIG; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART MUSCLE REPERFUSION; HEART RIGHT ATRIUM; HEART VENTRICLE ARRHYTHMIA; HEMODYNAMIC PARAMETERS; IN VITRO STUDY; IN VIVO STUDY; ISOLATED HEART; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REFRACTORY PERIOD; SUDDEN DEATH; VAGUS NERVE STIMULATION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; BENZOFURANS; DEATH, SUDDEN, CARDIAC; DOGS; ELECTRIC STIMULATION; FEMALE; GUINEA PIGS; INJECTIONS, INTRAVENOUS; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; POTASSIUM; RATS; RATS, SPRAGUE-DAWLEY; VAGUS NERVE; VENTRICULAR DYSFUNCTION;

EID: 12844261632     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000151899.03379.76     Document Type: Article

References (44)

1. Gill J, Heel RC, Fitton A. Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias. Drugs. 1992;43:69-110.
2. Singh BN. Antiarrhythmic drugs: re-orientation in light of recent developments in the control of disorders of rhythm. Am J Cardiol. 1998;81:3D-11D.
3. Charlier R. Cardiac actions in the dog of a new antagonist of adrenergic excitation which does not produce competitive blockade of adrenoceptors. Br J Pharmacol. 1970;39:668-674.
4. Polster P, Broekhuysen J. The adrenergic antagonism of amiodarone. Biochem Pharmacol. 1976;25:131-134.
5. Mason JW, Hondeghem LM, Katzung BG. Amiodarone blocks inactivated cardiac sodium channels. Pflugers Arch. 1983;396:79-81.
6. Nishimura M, Follmer CH, Singer DH. Amiodarone blocks calcium current in single guinea pig ventricular myocytes. J Pharmacol Exp Ther. 1989;251:650-659.
7. Kodama I, Kamika K, Toyama J. Cellular electropharmacology of amiodarone. Cardiovasc Res. 1997;35:13-29.
8. Vaughan Williams EM. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol. 1984;24:129-147.
9. Podrid PJ. Amiodarone: reevaluation of an old drug. Ann Intern Med. 1995;122:689-700.
10. Gautier P, Guillemare E, Djandjighian L, et al. In vivo and in vitro characterization of the novel antiarrhythmic agent SSR149744C: electrophysiological, anti-adrenergic and anti-angiotensin II effects. J Cardiovasc Pharmacol. 2004;44:244-257.
11. Manning AS, Bruyninckx C, Ramboux J, et al. SR33589, a new amiodarone-like agent: effect on ischemia- and reperfusion-induced arrhythmias in anesthetized rats. J Cardiovasc Pharmacol. 1995;26:453-461.
12. Nattel S, Liu L, St-Georges D. Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties. Cardiovasc Res. 1998;37:627-635.
13. Manoach M, Varon D, Tribulova N, et al. Hypokalemia as a simple reproducible model for sustained atrial fibrillation. J Mol Cell Cardiol. 1998;30:A4.
14. Manning AS, Coltart DJ, Hearse DJ. Ischemia and reperfusion-induced arrhythmias in the rat. Effects of xanthine oxidase inhibition with allopurinol. Circ Res. 1984;55:545-548.
15. Opitz CF, Mitchell GF, Pfeffer MA, et al. Arrhythmias and death after coronary artery occlusion in the rat. Continuous telemetric ECG monitoring in conscious, untethered rats. Circulation. 1995;92:253-261.
16. Cosnier-Pucheu S, Roccon A, Rizzoli G, et al. SSR149744C. a new antiarrhythmic drug, prevents experimental induced atrial fibrillation. Eur J Heart Fail. 2003;2:53.
17. Kane KA, Parratt JR, Williams FM. An investigation into the characteristics of reperfusion-induced arrhythmias in the anaesthetized rat and their susceptibility to antiarrhythmic agents. Br J Pharmacol. 1984;82:349-357.
18. Walker MJA, Curtis MJ, Hearse DJ, et al. The Lambeth Conventions: guidelines for the study of arrhythmias in ischaemia, infarction, and reperfusion. Cardiovasc Res. 1988;22:447-455.
19. Fabiani JN, Deloche A, Camilleri JP, et al. Protocole d'étude de l'ischémie aiguë du myocarde chez le rat. Ann Chir Thorac Cardiovasc. 1977;16:167-171.
20. Cosnier S, Guiraudou P, Grosjean J, et al. Amiodarone and droncdarone reduce early mortality in post M1 rats. Fund Clin Pharmacol. 1999; I3:73s.
21. Cosnier-Pucheu S, Guiraudou P, Rizzoli G, et al. Effects of amiodarone and dronedarone in the prevention of atrial arrhythmias in guinea pig isolated heart. Arch Mal Coeur Vaiss. 2001;94:21.
22. Finance O, Planchenault J, Bethegnies S, et al. Electrophysiological and anti-arrhythmic actions of a new amiodarone-like agent, dronedarone, in experimental atrial fibrillation. J Mol Cell Cardiol. 1998;30:A251.
23. Wang J, Feng J, Nattel S. Class III antiarhythmic drug action in experimental atrial fibrillation. Circulation. 1994;90:2032-2040.
24. Coumel P, Leclercq JF, Attuel P, et al. Autonomic influence in the genesis of atrial arrhythmias: atrial flutter and fibrillation of vagal origin. In: Narula DS ed. Cardiac arrhythmias: electrophysiology, diagnosis and management. Baltimore: Williams & Wilkins. 1979:243-255.
25. Li D, Zhang L, Kneller J, et al. Potential ionic mechanism for repolarization differences between canine right and left atrium. Circ Res. 2001;88:1168-1175.
26. + current in canine atrial myocytcs. Circ Res. 2003; 93:744-751.
27. + current by dofetilide. Circ Res. 1993;72:75-83.
28. Nattel S, Kneller J, Zou R, et al. Mechanisms of termination of atrial fibrillation by class I antiarrhythmic drugs: evidence from clinical, experimental and mathematical modeling studies. J Cardiovasc Electrophysiol. 2003;14:S133-S139.
29. Hayashi H, Fujiki A, Tani M, et al. Different effects of class Ic and III antiarrhythmic drugs on vagotonic atrial fibrillation in the canine heart. J Cardiovasc Pharmacol. 1998;31:101-107.
30. Weissenburger J, Davy JM, Chezalviel F. Experimental models of torsades de pointes. Fund Clin Pharmacol. 1993;7:29-38.
31. Helfant RH. Hypokalemia and arrhythmias. Am J Med. 1986;80: 13-22.
32. Tribulova N, Manoaeh M, Varon D, et al. Hypokalemia-induced ultrastructural, histochemical and connexin-43 alterations resulting in atrial and ventricular fibrillations. Gen Physiol Biophys. 1999; 18(Suppl):15-18.
33. Tani M, Shinmura K, Hasegawa H, et al. Effects of methylisobutyl amiloride on [Na+]i, reperfusion arrhythmias, and function in ischemic rat hearts. J Cardiovasc Pharmacol. 1996;27:794-801.
34. Sweies J, Omogbai EK, Smith GM. Occlusion and reperfusion-induced arrhythmias in rats: involvement of platelets and effects of calcium antagonists. J Cardiovasc Pharmacol. 1990;15:816-825.
35. 2+ influx. Eur J Pharmacol. 1999;365:233-239.
36. Brooks RR, Carpenter JF, Miller KE, et al. Efficacy of the class III antiarrhythmic agent azimilide in rodent models of ventricular arrhythmia. Proc Soc Exp Biol Med. 1996;212:84-93.
37. Chen J, Komori S, Li B, et al. IK independent class III actions of MS-551 compared with sematilide and dofetilide during reperfusion in anaesthetized rats. Br J Pharmcol. 1996;119:937-942.
38. Sarraf G, Barrett TD, Walker MJA. Tedisamil and lidocaine enhance each other's antiarrhythmic activity against ischemia-induced arrhythmias in rats. Br J Pharmacol. 2003;139:1389-1390.
39. Curtis MJ, Macleod BA, Walker MJ. Models for the study of arrhythmias in myocardial ischemia and infarction: the use of the rat. J Mol Cell Cardiol. 1987;19:399-419.
40. Clements-Jewery H, Hearse DJ, Curtis MJ. Independent contribution of catecholamines to arrythmogenesis during evolving infarction in the isolated rat heart. Br J Pharmacol. 2002;135:807-815.
41. Nattel S, Bourne G, Talajic M. Insights into mechanisms of antiarrhythmic drug action from experimental models of atrial fibrillation. J Cardiovasc Electrophysiol. 1997;8:469-480.
42. Gill J, Heel RC, Fitton A. Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias. Drugs. 1992;43:69-110.
43. Merot J, Charpentier F, Poirier JM, et al. Effects of chronic treatment by amiodarone on transmural heterogeneity of canine ventricular repolarization in vivo: interaction with acute sotalol. Cardiovasc Res. 1999;44:303-314.
44. Varro A, Takaes J, Nemeth M, et al. Electrophysiological effects of dronedarone, a noniodinated amiodarone derivative in the canine heart: comparison with amiodarone. Br J Pharmacol. 2001;133:625-634.